Cargando…

Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma

Double-hit lymphoma (DHL) is among the most aggressive and chemoresistant lymphoma subtypes. DHLs carry genomic abnormalities in MYC, BCL2, and/or BCL6 oncogenes. Due to the simultaneous overexpression of these driver oncogenes, DHLs are highly resistant to frontline therapies. Most DHLs overexpress...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yuanhui, Azizian, Nancy G., Dou, Yaling, Pham, Lan V., Li, Yulin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868798/ https://www.ncbi.nlm.nih.gov/pubmed/31752970 http://dx.doi.org/10.1186/s13045-019-0803-9

Ejemplares similares

Rational targeted therapeutics for double-hit lymphoma
por: Azizian, Nancy G, et al.
Publicado: (2019)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
por: Li, Weiping, et al.
Publicado: (2019)

XPO1-dependent nuclear export as a target for cancer therapy
por: Azizian, Nancy G., et al.
Publicado: (2020)

Comparison of HIT Tests in Patients with COVID-19 and Thrombocytopenia
por: Abudouleh, Esra’a, et al.
Publicado: (2022)

Targeting MYC and BCL2 by a natural compound for “double‐hit” lymphoma
por: Liu, Xiaoqian, et al.
Publicado: (2022)

Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
por: Brinton, Lindsey T., et al.
Publicado: (2020)

Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma
por: Huang, Sixia, et al.
Publicado: (2019)

Establishment and characterization of a novel MYC/BCL2 “double-hit” diffuse large B cell lymphoma cell line, RC
por: Pham, Lan V., et al.
Publicado: (2015)

BFL-1 expression determines the efficacy of venetoclax in MYC+/BCL2+ double hit lymphoma
por: Esteve-Arenys, Anna, et al.
Publicado: (2018)

Double-hit lymphoma (rearrangements of MYC, BCL-2) during pregnancy: A case report
por: Xie, Fan, et al.
Publicado: (2021)

Double‑hit primary lymphoma (MYC and BCL2) in the bilateral ovary: A case report
por: Zhang, Yan, et al.
Publicado: (2023)

Increased Frequencies of Gene and Chromosome Mutations after X‐Irradiation in Mouse Embryonal Carcinoma Cells Transfected with the bcl‐2 Gene
por: Taga, Masataka, et al.
Publicado: (2000)

Development of novel 5-FU modified siRNA against BCL-2 with enhanced efficacy and vehicle-free cellular uptake
por: Fesler, Andrew, et al.
Publicado: (2022)

Pharmacological targeting PIKfyve and tubulin as an effective treatment strategy for double-hit lymphoma
por: Feng, Liying, et al.
Publicado: (2022)

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
por: Li, Xin, et al.
Publicado: (2018)

Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems
por: Shang, Enyuan, et al.
Publicado: (2018)

Educational Case: Gastric High-Grade B-Cell Lymphoma With MYC and BCL2 Gene Rearrangement (Double-Hit Lymphoma)
por: Betts, Elham Vali, et al.
Publicado: (2020)

A network based efficient drug repurposing strategy for targeting diabesity
por: Dutta, Subhajit, et al.
Publicado: (2022)

Rare double-hit with two translocations involving IGH both, with BCL2 and BCL3, in a monoclonal B-cell lymphoma/leukemia
por: Alpatov, Roman, et al.
Publicado: (2015)

Time-to-treatment of diffuse large B-cell lymphoma in São Paulo
por: Xavier, Flávia Dias, et al.
Publicado: (2014)

Advancing the management of double hit lymphoma
por: Landsburg, Daniel J.
Publicado: (2017)

Drug therapy for double-hit lymphoma
por: Phuoc, Vania, et al.
Publicado: (2019)

Simultaneous Expression of T‐Cell and Myeloid Cell Phenotypes in Eight Newly Established HTLV‐I‐positive T‐Cell Lines
por: Koizumi, Shigeki, et al.
Publicado: (1992)

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
por: Wang, Michael L., et al.
Publicado: (2023)

Altered pathways and targeted therapy in double hit lymphoma
por: Zhuang, Yuxin, et al.
Publicado: (2022)

Simultaneous determination of cotinine and trans-3-hydroxycotinine in urine by automated solid-phase extraction using gas chromatography–mass spectrometry
por: Chiadmi, Fouad, et al.
Publicado: (2014)

Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma
por: Li, Shaoying, et al.
Publicado: (2016)

Inhibition of VEGFR2 overcomes venetoclax-resistance in diffuse large B-cell lymphoma cells
por: Shi, Yuanfei, et al.
Publicado: (2022)

Non-target time trend screening: a data reduction strategy for detecting emerging contaminants in biological samples
por: Plassmann, Merle M., et al.
Publicado: (2016)

High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma
por: ZL, Wu, et al.
Publicado: (2011)

Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population
por: Lopes, Lisandro F, et al.
Publicado: (2012)

The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients
por: Kim, Seok Jin, et al.
Publicado: (2015)

Increased Expression of ras Genes in Non‐Hodgkin's Lymphomas Is not Associated with Oncogenic Activation of Those Genes by Point Mutation
por: Hamatani, Kiyohiro, et al.
Publicado: (1989)

Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors
por: Trkulja, Kyla L., et al.
Publicado: (2023)

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
por: Hutchings, Martin, et al.
Publicado: (2021)

MYC/BCL2 double- and MYC/BCL2/BCL6 triple-hit follicular lymphomas associated with t(8;14;18)(q24;q32;q21)
por: Takeoka, Kayo, et al.
Publicado: (2022)

CD5+ follicular lymphoma rapidly transformed to high-grade B-cell lymphoma with double-hit: from BCL2 to MYC disruption
por: Soler-Espejo, Eva, et al.
Publicado: (2023)

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
por: Bachy, Emmanuel, et al.
Publicado: (2019)

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
por: Wang, Michael, et al.
Publicado: (2021)

Transient HSP90 inhibition enhances the sensitivity of mantle cell lymphoma to poly (ADP-ribose) polymerase (PARP) inhibitors
por: Shi, Chaowen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5uq6tnbcpkq9t2kb3gqabo8dk7